Cardiac involvement in eosinophilic granulomatosis with polyangitis (Churg Strauss) (RCD code: I-3A.7a)
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2013, Vol 1, Issue 3
Abstract
Eosinophilic granulomatosis with polyangitis – EGPA (previously known as Churg‑Strauss syndrome) is a rare, systemic, necrotizing small‑vessel vasculitis with accompanying bronchial asthma, eosinophilia and eosinophilic tissue infiltration of various tissues with granuloma formation. The pathognomonic laboratory feature of EGPA is prominent peripheral eosinophilia that commonly exceed 1,500 cells/μl, and the presence in approximately 40% of patients of the antineutrophil autoantibodies (ANCA). EGPA is one of the most common of the systemic vasculitides to affect the heart and if present it deteriorates the prognosis of the disease and increases mortality. Cardiac involvement varies widely ranging from 16–92% and is more common in ANCA negative patients. The cardiac manifestations varies in its clinical presentation. It may present as myocarditis with cardiomyopathy, pericarditis with pericardial effusion (up to 25% of patients), heart failure (18%),varies ventricular and supraventricular arrhythmias, valve involvement and sudden cardiac death. Epicardial coronary arteries involvement is rare, however, coronary angiography should be considered in patients presenting with angina symptoms to rule out important coronary vessels stenosis. Imaging techniques as transthoracic echocardiography (TTE) and cardiac magnetic resonance (CMR) may help in establishing the diagnosis of EGPA. The significance of often detected cardiac damage in CMR without clinical manifestation remains uncertain, however, some preliminary studies suggest that, these patients should be treated more intensively to prevent further cardiac involvement.The main treatment of EGPA consist of corticosteroids and additional immunosuppression in patients with worse prognosis. In differential diagnosis other forms of vasculitides and hypereosinophilic syndromes (HES) that may also affect the heart should be excluded.
Authors and Affiliations
Wojciech Szczeklik, Tomasz Miszalski-Jamka
Keywords
Related Articles
- EP ID EP245385
- DOI 10.20418/jrcd.vol1no3.56
- Views 83
- Downloads 0
JRCD is now an open‑access journal and also accepts high‑quality papers beyond the field of rare cardiovascular diseases and disorders
n/a
The 4th Conference of Working Group in Congenital Heart Diseases of Polish Society of Cardiology
Congenital heart disease (CHD) is the most common developmental anomaly and represents about 1% of all live-born children. Recent progress in cardiac surgery and pediatric cardiology has resulted in large numbers of adu...
Hypertrophic cardiomyopathy – symptomatic atrial fibrillation in a patient at high risk of sudden cardiac death
We present the case of a young patient with significant left ventricular hypertrophy as a common representation of the hypertrophic cardiomyopathy (HCM) phenotype. The clinical presentation and diagnostic route of the di...
Pulmonary arterial hypertension: management in specific medical conditions
Pulmonary arterial hypertension (PAH) is a severe and progressive disease. Due to the narrowing of the blood vessels in the lungs, pul- monary vascular resistance and pulmonary pressures increase. This results in reduced...
Journal of Rare Cardiovascular Diseases: “One finger cannot lift a pebble” – cooperation as the only way to move forward
Dear Readers,Gaining more experience and exchange of knowledge in one thing is the only way to advance the field of rare cardiovascular diseases (RCD). Taking care of RCD patients on a daily basis quickly leads to realiz...